Literature DB >> 7721874

Identification of an inhibitor of tissue-type plasminogen activator-mediated fibrinolysis in human neutrophils. A role for defensin.

A A Higazi1, I I Barghouti, R Abu-Much.   

Abstract

An inhibitor of tissue-type plasminogen activator (tPA)-mediated and plasminogen-dependent fibrinolysis was isolated from human neutrophils. On a G-50 gel filtration column, the antifibrinolytic activity present in neutrophil homogenates comigrated with proteins of < 13 kDa. The inhibitory fraction had only a slight effect on urokinase with plasminogen- or plasmin-mediated fibrinolysis and no effect on urokinase- or plasmin-mediated cleavage of H-D-valyl-L-leucyl-L-lysine-p-nitroanilide (S-2251). The neutrophil-derived fraction inhibited tPA with plasminogen activity on S-2251 but not on H-D-isoleucyl-L-prolyl-L-arginine-p-nitroanilide (S-2288). The inhibition of tPA-mediated and plasminogen-dependent fibrinolysis or S-2251 cleavage showed a competitive pattern and could be relieved by increasing the concentration of plasminogen. The same fraction also inhibited binding of plasminogen to fibrin. Consecutive purification steps revealed that the molecular mass of the inhibitor was 1-5-kDa. Polylysine-Sepharose affinity chromatography indicated that the inhibitor is a protein of 4 kDa, migrating as one band on SDS-polyacrylamide gel electrophoresis. Amino acid sequence analysis of this band showed the presence of two sequences, differing by one amino acid, which are identical to defensin I and II. Comparison of the sequences of plasminogen and defensin showed homology of defensin to the plasminogen kringles known to contain the lysine binding sites. The close structural similarity between defensin and plasminogen kringles and the ability of defensin to compete with plasminogen on binding to fibrin explain the ability of defensin to inhibit tPA-mediated, plasminogen-dependent fibrinolysis. These results suggest that the antifibrinolytic activity of defensin may have a biological function in preventing the spread of infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7721874     DOI: 10.1074/jbc.270.16.9472

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  α-Defensins Induce a Post-translational Modification of Low Density Lipoprotein (LDL) That Promotes Atherosclerosis at Normal Levels of Plasma Cholesterol.

Authors:  Rami Abu-Fanne; Emad Maraga; Ihab Abd-Elrahman; Aviel Hankin; Galia Blum; Suhair Abdeen; Nuha Hijazi; Douglas B Cines; Abd Al-Roof Higazi
Journal:  J Biol Chem       Date:  2015-10-30       Impact factor: 5.157

2.  tPA regulates pulmonary vascular activity through NMDA receptors.

Authors:  Taher Nassar; Khalil Bdeir; Serge Yarovoi; Rami Abu Fanne; Juan-Carlos Murciano; Steven Idell; Timothy Craig Allen; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-05-13       Impact factor: 5.464

3.  Neutrophil α-defensins promote thrombosis in vivo by altering fibrin formation, structure, and stability.

Authors:  Rami Abu-Fanne; Victoria Stepanova; Rustem I Litvinov; Suhair Abdeen; Khalil Bdeir; Mohamed Higazi; Emad Maraga; Chandrasekaran Nagaswami; Alexander R Mukhitov; John W Weisel; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Blood       Date:  2018-11-15       Impact factor: 22.113

4.  Immunohistochemical localization of defensin in human coronary vessels.

Authors:  E S Barnathan; P N Raghunath; J E Tomaszewski; T Ganz; D B Cines
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

5.  Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice.

Authors:  Nuha Hijazi; Rami Abu Fanne; Rinat Abramovitch; Serge Yarovoi; Muhamed Higazi; Suhair Abdeen; Maamon Basheer; Emad Maraga; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Blood       Date:  2015-02-11       Impact factor: 22.113

6.  Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and Thrombus.

Authors:  Quanyin Hu; Chenggen Qian; Wujin Sun; Jinqiang Wang; Zhaowei Chen; Hunter N Bomba; Hongliang Xin; Qundong Shen; Zhen Gu
Journal:  Adv Mater       Date:  2016-09-14       Impact factor: 30.849

7.  Neutrophil alpha-defensins cause lung injury by disrupting the capillary-epithelial barrier.

Authors:  Khalil Bdeir; Abd Al-Roof Higazi; Irina Kulikovskaya; Melpo Christofidou-Solomidou; Sergei A Vinogradov; Timothy C Allen; Steven Idell; Rose Linzmeier; Tomas Ganz; Douglas B Cines
Journal:  Am J Respir Crit Care Med       Date:  2010-01-21       Impact factor: 21.405

8.  Regulation of airway contractility by plasminogen activators through N-methyl-D-aspartate receptor-1.

Authors:  Taher Nassar; Serge Yarovoi; Rami Abu Fanne; Sa'ed Akkawi; Mahmud Jammal; Timothy Craig Allen; Steven Idell; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-22       Impact factor: 6.914

9.  Blood-brain barrier permeability and tPA-mediated neurotoxicity.

Authors:  Rami Abu Fanne; Taher Nassar; Sergei Yarovoi; Anwar Rayan; Itschak Lamensdorf; Michael Karakoveski; Polianski Vadim; Mahmud Jammal; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Neuropharmacology       Date:  2010-01-06       Impact factor: 5.250

10.  Alpha-defensins: risk factor for thrombosis in COVID-19 infection.

Authors:  Suhair Abdeen; Khalil Bdeir; Rami Abu-Fanne; Emad Maraga; Mohamed Higazi; Nigar Khurram; Michael Feldman; Charuhas Deshpande; Leslie A Litzky; Samuel N Heyman; Kathleen T Montone; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Br J Haematol       Date:  2021-05-30       Impact factor: 8.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.